News

Linnaeus Therapeutics Scientific Cofounders Publish Preclinical Pancreatic Cancer Data in Cellular and Molecular Gastroenterology and Hepatology Haddonfield NJ, June 10, 2020 -- Linnaeus Therapeutics, Inc. (Linnaeus), a privately [...]

Linnaeus Therapeutics Announces First Patient Dosed in Its Phase 1/2 Clinical Trial of LNS8801 in Patients with Advanced Cancer Company Commences First-in-Human Study at Multiple Academic [...]

Linnaeus Therapeutics Announces FDA Clearance of Investigational New Drug Application for LNS8801 Haddonfield NJ, September 24, 2019--Linnaeus Therapeutics, Inc. (Linnaeus), a privately held, clinical-stage biopharmaceutical company [...]

Linnaeus Therapeutics Closes $12 Million Series B Financing Linnaeus Therapeutics, Inc. ("Linnaeus"), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule [...]

Linnaeus Therapeutics Scientific Cofounder Presents Preclinical Pancreatic Cancer Data at AACR Pancreas Cancer Meeting Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development [...]

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced it has been awarded a Phase 2 Small Business Innovation Research (“SBIR”) Award by the National Cancer Institute (“NCI”) of the National Institute for Health (“NIH”).